Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis
Open Access
- 1 January 2009
- journal article
- Published by Springer Science and Business Media LLC in Arthritis Research & Therapy
- Vol. 11 (4), R123
- https://doi.org/10.1186/ar2789
Abstract
In the present study we evaluated changes in the B cell phenotype in peripheral blood and bone marrow (BM) of patients with rheumatoid arthritis (RA) following anti-CD20 treatment using rituximab.Keywords
This publication has 47 references indexed in Scilit:
- Is the blood B-cell subset profile diagnostic for Sjögren syndrome?Annals Of The Rheumatic Diseases, 2008
- Phenotypic and functional heterogeneity of human memory B cellsSeminars in Immunology, 2008
- Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker resultsAnnals Of The Rheumatic Diseases, 2007
- Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of responseAnnals Of The Rheumatic Diseases, 2007
- Mature B cells class switched to IgD are autoreactive in healthy individualsJCI Insight, 2007
- BAFF‐modulated repopulation of B lymphocytes in the blood and salivary glands of RITUXIMAB‐TREATED patients with Sjögren's syndromeArthritis & Rheumatism, 2007
- Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeksArthritis & Rheumatism, 2006
- Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeysTransplant Immunology, 2003
- Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALLLeukemia, 1999
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988